>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
CT7:多发性骨髓瘤预后判断及治疗新方向
作者:张李玉1  欧阳建2  陈兵2 
单位:1. 东南大学医学院, 江苏 南京 210009;
2. 南京大学医学院附属南京鼓楼医院血液科, 江苏 南京 210008
关键词:多发性骨髓瘤 癌睾丸抗原 癌睾丸抗原7 文献综述 
分类号:R733.3;R730.5
出版年·卷·期(页码):2015·34·第四期(666-669)
摘要:

多发性骨髓瘤是难以治愈的骨髓恶性浆细胞增殖性疾病,严重威胁患者的生活质量。癌睾丸抗原(CTAs)是一类肿瘤相关性抗原,在多发性骨髓瘤细胞株以及多发性骨髓瘤患者骨髓标本中检测到多种CTAs表达,其中癌睾丸抗原7(CT7)的表达最为显著。研究发现 CT7表达阳性的患者临床预后相对较差,同时CT7有助于肿瘤细胞逃避凋亡,因此人们认为CT7有望成为靶向治疗的目标。

参考文献:

[1] RIA R,REALE A,VACCA A.Novel agents and new therapeutic approaches for treatment of multiple myeloma[J].World J Methodol,2014,4(2):73-90.
[2] VINCENT RAJKUMAR S.Multiple myeloma:2014 update on diagnosis,risk-stratification,and management[J].Am J Hematol,2014,89(10):999-1009.
[3] 包芳,吴学宾.4例 IgD型多发性骨髓瘤临床报道及文献复习[J].现代医学,2011,39(1):51-53.
[4] KELLNER J,LIU B,KANG Y,et al.Fact or fiction-identifying the elusive multiple myeloma stem cell[J].J Hematol Oncol,2013,6:91.
[5] CABALLERO O L,CHEN Y T.Cancer/testis (CT) antigens:potential targets for immunotherapy[J].Cancer Sci,2009,100(11):2014-2021.
[6] Van Der BRUGGEN P,TRAVERSARI C,CHOMEZ P,et al.A gene encoding an antigen recgnized by cytolytic T lymphocytes on a human melanoma[J].Science,1991,254(5038):1643-1647.
[7] SAHIN U,TURECI O,PFREUNDSCHUH M.Serological identification of human tumor antigens[J].Curr Opin Immunol,1997,9(5):709-716.
[8] COSTA F F,Le BLANC K,BRODIN B.Concise review:cancer/testis antigens,stem cells,and cancer[J].Stem Cells,2007,25(3):707-711.
[9] STEVENSON B J,ISELI C,PANJI S,et al.Rapid evolution of cancer/testis genes on the X chromosome[J].BMC Genomics,2007,8:129.
[10] SCANLAN M J,SIMPSON A J,OLD L J.The cancer/testis genes:review,standardization,and commentary[J].Cancer Immun,2004,4:1.
[11] HOFMANN O,CABALLERO O L,STEVENSON B J,et al.Genomewide analysis of cancer/testis gene expression[J].Proc Natl Acad Sci USA,2008,105(51):20422-20427.
[12] CHEN Y T,GURE A O,TSANG S,et al.Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library[J].Proc Natl Acad Sci USA,1998,95(12):6919-6923.
[13] LUCAS S,De SMET C,ARDEN K C,et al.Identification of a new MAGE gene with tumor-specific expression by representational difference analysis[J].Cancer Res,1998,58(4):743-752.
[14] JUNGBLUTH A A,CHEN Y T,BUSAM K J,et al.CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues[J].Int J Cancer,2002,99(6):839-845.
[15] De CARVALHO F,COSTA E T,CAMARGO A A,et al.Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines[J].PLoS One,2011,6(11):e27707.
[16] ANDRADE V C,VETTORE A L,FELIX R S,et al.Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients[J].Cancer Immun,2008,8:2.
[17] ATANACKOVIC D,LUETKENS T,HILDEBRANDT Y,et al.Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma[J].Clin Cancer Res,2009,15(4):1343-1352.
[18] CHO H J,CABALLERO O L,GNJATIC S,et al.Physical interaction of two cancer-testis antigens,MAGE-C1(CT7) and NY-ESO-1(CT6)[J].Cancer Immun,2006,6:12.
[19] TINGUELY M,JENNI B,KNIGHTS A,et al.MAGE-C1/CT-7 expression in plasma cell myeloma:sub-cellular localization impacts on clinical outcome[J].Cancer Sci,2008,99(4):720-725.
[20] JUNGBLUTH A A,ELY S,DILIBERTO M,et al.The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation[J].Blood,2005,106(1):167-174.
[21] De CARVALHO F,ALÜES V L,BRAGA W M,et al.MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy[J].Cancer Immunol Immunother,2013,62(1):191-195.
[22] ROSENZWEIG M A,LANDAU H,SELDIND,et al.Cancer-testis antigen expression and immunogenicity in AL amyloidosis[J].Blood Cancer J,2012,2:e90.
[23] CURIONI-FONTECEDRO A,NUBER N,MIHIC-PROBST D,et al.Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients[J].PLoS One,2011,6(6):e21418.
[24] ZHANG Y,BAO L,LU J,et al.The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma[J].Mol Cancer,2014,13:25.
[25] PABST C,ZUSTIN J,JACOBSEN F,et al.Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma[J].Exp Mol Pathol,2010,89(2):175-181.
[26] NUBER N,CURIONI-FONTECEDRO A,MATTERA C,et al.Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients[J].Proc Natl Acad Sci USA,2010,107(34):15187-15192.
[27] NUBER N,CURIONI-FONTECEDRO A,DANNENMANN S R,et al.MAGE-C1/CT7 spontaneously triggers a CD4+T-cell response in multiple myeloma patients[J].Leukemia,2013,27(8):1767-1769.
[28] CURIONI-FONTECEDRO A,KNIGHTS A J,TINGUELY M,et al.MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma[J].Leukemia,2008,22(8):1646-1648.
[29] LENDVAI N,GNJATIC S,RITTER E,et al.Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients[J].Cancer Immun,2010,10:4.
[30] ATANACKOVIC D,HILDEBRANDT Y,JADCZAK A,et al.Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells[J].Haematologica,2010,95(5):785-793.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 186127 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364